Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
<h4>Background and objectives</h4>Five-tumour necrosis factor (TNF)-blockers (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab) are available for treatment of rheumatoid arthritis. Only few clinical trials compare one TNF-blocker to another. Hence, a systematic review...
Main Authors: | Kalle J Aaltonen, Liisa M Virkki, Antti Malmivaara, Yrjö T Konttinen, Dan C Nordström, Marja Blom |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22272322/pdf/?tool=EBI |
Similar Items
-
The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review.
by: Jaana T Joensuu, et al.
Published: (2015-01-01) -
Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
by: Saara Huoponen, et al.
Published: (2019-01-01) -
Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
by: R. Caporali, et al.
Published: (2011-09-01) -
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.
by: Taylor, P, et al.
Published: (2009) -
Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
by: Fragoulakis V, et al.
Published: (2015-01-01)